SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 12, 2024 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, according to a study published online Dec. 11 in the New England Journal of Medicine to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
Komal L. Jhaveri, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a phase 3 trial enrolling 874 patients with ER-positive, HER2-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 inhibitor. Patients were randomly assigned to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib (331, 330, and 213 patients, respectively). Investigator-assessed progression-free survival was compared for imlunestrant versus standard therapy among 256 patients with ESR1 mutations and among all patients.
The researchers found that among the 256 patients with ESR1 mutations, median progression-free survival was 5.5 and 3.8 months with imlunestrant and standard therapy, respectively. The corresponding estimated restricted mean survival time was 7.9 and 5.4 months at 19.4 months. In the overall population, median progression-free survival was 5.6 and 5.5 months with imlunestrant and standard therapy, respectively (hazard ratio for progression or death, 0.87; 95 percent confidence interval, 0.72 to 1.04; P = 0.12). Comparing imlunestrant-abemaciclib with imlunestrant, median progression-free survival was 9.4 and 5.5 months, respectively (hazard ratio for progression or death, 0.57; 95 percent confidence interval, 0.44 to 0.73; P < 0.001).
"Imlunestrant therapy significantly improved progression-free survival over standard therapy among patients with ESR1 mutations," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures imlunestrant and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
Exercise, Rehab Services Can Be Integrated Into Breast Cancer Care
MONDAY, April 28, 2025 -- Exercise and rehabilitation services for patients with breast cancer through a clinical workflow algorithm called CORE (Comprehensive Oncology...
Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema
THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema (BCRL), according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.